SIGY Sigyn Therapeutics Inc.
Company Updates ·
Oragenics signed a non-binding letter of intent to license certain indications of CardioDialysis from Sigyn Therapeutics for traumatic brain injury. The proposed terms include 3,250,000 restricted preferred shares and a 3% royalty for six years.
Sigyn Therapeutics filed a Form 12b-25 notice on August 15, 2025 saying it cannot file its quarterly report for the period ended June 30, 2025 on time. It promises to file no later than five days after the original due date.
Sigyn Therapeutics Inc. develops medical devices to treat cancer and infectious disease disorders through extracorporeal blood purification. Its lead therapeutic candidate, Sigyn Therapy, is designed to extract deadly pathogens and toxins from a patient's bloodstream while also dampening excessive immune responses associated with life-threatening infections. The text says Sigyn Therapy has been validated to extract viral pathogens, bacterial toxins including endotoxin, hepatic toxins and inflammatory cytokines from human blood plasma. The company targets untreatable viral pathogens, antibiotic-resistant bacterial infections, endotoxemia and sepsis. First-in-human studies are planned in end-stage renal disease patients with endotoxemia and concurrent inflammation. Sigyn Therapy is also proposed for xenotransplantation, in gene-edited donor pigs and in human transplant recipients, to reduce the spread of infection. In cancer, the company develops devices rather than drugs. ImmunePrep is meant to enhance immunotherapeutic antibodies, ChemoPrep to reduce tumor-derived exosomes before chemotherapy, and ChemoPure to remove off-target chemotherapy from the bloodstream.
| Product or program | What it is | Stage |
|---|---|---|
| Sigyn Therapy | Blood purification to extract pathogens, toxins and cytokines from plasma | Pre-clinical; first-in-human studies planned |
| ImmunePrep | Immobilizes therapeutic antibodies in an extracorporeal circuit to sweep out decoys | |
| ChemoPrep | Reduces tumor-derived exosomes before chemotherapy administration | |
| ChemoPure | Extracts off-target chemotherapy from the bloodstream to reduce toxicity |
| Line | FY2024 | FY2023 |
|---|---|---|
| Research and development | $773,279 | $798,165 |
| Net income (loss) | -$3.3 million | -$4.1 million |
| Cash from operations | -$872,436 | -$1.4 million |
| Cash and equivalents | $12,144 | $11,690 |
Sigyn Therapeutics Inc. trades under the ticker SIGY on OTC.
Sigyn Therapeutics Inc. is listed on OTC.
The SEC Central Index Key (CIK) for Sigyn Therapeutics Inc. is 1642159. Its filings are on SEC EDGAR.
1,605,377 shares as of 2025-11-14, per the cover page of its 10-Q filed 2025-11-14.
Our directory records Sigyn Therapeutics Inc. under United States.
Our directory classifies Sigyn Therapeutics Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Sigyn Therapeutics Inc. is US82674U2050.
aibio.space lists Sigyn Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Sigyn Therapeutics Inc. develops medical devices to treat cancer and infectious disease disorders through extracorporeal blood purification. Its lead therapeutic candidate, Sigyn Therapy, is designed to extract deadly pathogens and toxins from a patient's bloodstream while also dampening excessive immune responses associated with life-threatening infections.
Sigyn Therapy: Blood purification to extract pathogens, toxins and cytokines from plasma Stage: Pre-clinical; first-in-human studies planned.
ImmunePrep: Immobilizes therapeutic antibodies in an extracorporeal circuit to sweep out decoys Stage: Not stated.
Sigyn Therapeutics Inc. reported a net loss of $3.3 million for the fiscal year ended Dec 31, 2024, and used $872,436 of cash in operations, per its annual report to the SEC.
$773,279 in the fiscal year ended Dec 31, 2024, per its annual report.
$85,571 in cash at Sep 30, 2025, per its 10-Q.
Filed to end its SEC reporting. SEC Form 15-12G. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio